Our objective was to explore the Odds Ratios (OR) associated with all-grade and grade 3–5 CIP in patients with advanced NSCLC undergoing treatment with PD-1/PDL-1 or CTLA-4 inhibitors. This evidence concerns the gene PDCD1 and hereditary sensory and autonomic neuropathy.